News
NEJM Publishes Phase 3 MARIPOSA Trial: Amivantamab plus Lazertinib Sets New Standard in EGFR-Mutant NSCLC
Through global collaboration with multinational pharmaceutical companies, a domestically developed anticancer drug has once again been published in the world-renowned New England Journal of Medicine
Yuhan Signs HIV Drug API Supply Contract with Gilead
On the 20th, Yuhan Corporation announced that it has signed a contract with multinational pharmaceutical company Gilead Sciences to supply the active pharmaceutical ingredient (API)
Lazertinib + SBRT Shows Promising Results in EGFR-Mutant Oligometastatic NSCLC
A phase 2 clinical trial led by Korean investigators demonstrated that combining the third-generation EGFR inhibitor lazertinib (Leclaza® in Korea, Lazcluzy® internationally) with stereotactic body
Amivantamab + Lazertinib Shows Significant Benefits in EGFR-Mutant NSCLC
Johnson & Johnson’s Innovative Medicine (formerly Janssen) reported that the combination of amivantamab (Rybrevant®) and lazertinib (Leclaza® in Korea, Lazcluze® internationally), developed by Yuhan Corporation,
Janssen Gains China Approval for Lazertinib + Amivantamab Combo in EGFR-Mutant NSCLC
Date: 08/01/25 Yuhan Corporation’s novel EGFR-targeting non-small cell lung cancer (NSCLC) therapy Leclaza (lazertinib) has received official marketing approval in China, further solidifying its global
Yuhan Presents Phase 1b Part 2 Results for Lesigercept – Shows Efficacy in Omalizumab-Refractory Patients
Date: 6/13/25 Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in